Compared with doxorubicin plus cyclophosphamide, docetaxel plus cyclophosphamide was highly cost-effective for adjuvant treatment of operable breast cancer.
Lei Chen, MD, PhD
Advertisement
Articles by Lei Chen, MD, PhD
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Docetaxel-Cyclophosphamide Versus Doxorubicin-Cyclophosphamide for Breast Cancer
Published: October 1st 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
2
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
3
Medetomidine: The Demon in the Illicit Fentanyl Supply
4
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
5
